Genelux Corporation
(GNLX)
undefined
undefined%
At close: undefined
2.49
6.82%
After-hours Dec 13, 2024, 05:34 PM EST
Company Description
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types.
Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer.
The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer.
The company was incorporated in 2001 and is headquartered in Westlake Village, California.
Genelux Corporation
| Country | United States |
| IPO Date | Jan 26, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 24 |
| CEO | Thomas Zindrick J.D. |
Contact Details
Address: 2625 Townsgate Road Westlake Village, California United States | |
| Website | https://www.genelux.com |
Stock Details
| Ticker Symbol | GNLX |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | 0001231457 |
| CUSIP Number | |
| ISIN Number | US36870H1032 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Thomas Zindrick J.D. | Chairman, Chief Executive Officer & President |
| Lourie S. Zak | Chief Financial Officer |
| Dr. Joseph Cappello Ph.D. | Chief Technical Officer |
| Dr. Yong Yu Ph.D. | Senior Vice President of Clinical Development |
| Prof. Paul Scigalla M.D., Ph.D. | Chief Medical Officer |
| Ralph Smalling B.Sc. | Vice President & Head of Regulatory Affairs |
| Sean Ryder J.D. | General Counsel & Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Nov 08, 2024 | 8-K | Current Report |
| Oct 25, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Oct 22, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Oct 21, 2024 | 4 | Filing |
| Oct 03, 2024 | 8-K | Current Report |
| Sep 26, 2024 | 4/A | [Amend] Filing |
| Sep 13, 2024 | 4 | Filing |
| Sep 12, 2024 | 4 | Filing |
| Sep 11, 2024 | 4 | Filing |